Schizophrenia - Future Research (1)

Professor Daniel Weinberger predicts that because of recent progress in genomic research, the future for schizophrenic research is extremely promising.

I believe the future is brighter for schizophrenia research than at any time since there has been schizophrenia research. The reason for this is that we now, for the first time after well over a century of dedicated researchers studying this disease, have the first truly objective clues to the basic mechanisms of causation and that is the genes. Genes are clues to the biological and biochemical pathways in cells that build our brains. We assume then in schizophrenia something about the building and wiring of these brains has gone slightly and subtly awry. The genes will provide us with ways to understand these derangements. We’ve never had this before. Genes will identify people at risk, genes will hopefully identify strategies that might allow better intervention and prevention. Genes should identify new targets for the development of new drugs, not by changing the genes but every gene is an entry point into a biochemical pathway in a cell. Many of these genes will converge on critical nodes in these pathways. Cells are complicated biological machines. We will look for certain critical nodes in these pathways that can be targeted by new drugs. So these are extraordinary opportunities now in schizophrenia research to define basic mechanisms of disease, to identify at risk people, to more judiciously treat people based on genetic variation, and to find and discover new targets for therapy.

schizophrenia, future, research, gene, brain, cell, medicine, pathway, treatment, drug, daniel, weinberger

Related Content

1173. Glutamate and Schizophrenia

Professor Daniel Weinberger discusses evidence from a number of research areas that highlight the importance of the neurotransmitter glutamate in schizophrenia.

  • ID: 1173
  • Source: G2C

1165. Dopamine and Schizophrenia

Professor Daniel Weinberger explains that dopamine is the major focus of biochemical research into schizophrenia.

  • ID: 1165
  • Source: G2C

1169. COMT expression

Professor Daniel Weinberger explains that the schizophrenia candidate gene, COMT, is abundantly expressed in the hippocampus and prefrontal cortex.

  • ID: 1169
  • Source: G2C

1172. Neuregulin and Schizophrenia

Professor Daniel Weinberger discusses research that makes neuregulin a candidate gene for schizophrenia.

  • ID: 1172
  • Source: G2C

2226. Schizophrenia

An overview of schizophrenia-related content on Genes to Cognition Online.

  • ID: 2226
  • Source: G2C

1168. COMT and Schizophrenia

Professor Daniel Weinberger explains why the gene COMT, which detoxifies dopamine, is a candidate gene for schizophrenia.

  • ID: 1168
  • Source: G2C

1166. N-Acetylaspartate and Schizophrenia

Professor Daniel Weinberger discusses the role played by the biochemical N-Acetylaspartate in schizophrenia.

  • ID: 1166
  • Source: G2C

822. The Amygdala, the Body's Alarm Circuit

The amygdala controls autonomic responses associated with fear, arousal, and emotional stimulation and has been linked to anxiety disorder and social phobias.

  • ID: 822
  • Source: G2C

2293. Genes and Treatment for Depression and Anxiety

Doctor Daniel Pine estimates that approximately 30-50% of the risk for anxiety and depression is genetic. Genetic treatments are an exciting area of research currently.

  • ID: 2293
  • Source: G2C

846. Treatments for Schizophrenia

Many psychiatrists are now prescribing second-generation or 'atypical' antipsychotics.

  • ID: 846
  • Source: G2C